Literature DB >> 33894837

Cagrilintide plus semaglutide for obesity management.

Sara Becerril1, Gema Frühbeck2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33894837     DOI： 10.1016/S0140-6736(21)00944-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  Mediators of Amylin Action in Metabolic Control.

Authors:  Christina N Boyle; Yi Zheng; Thomas A Lutz
Journal:  J Clin Med       Date:  2022-04-15       Impact factor: 4.964

2.  Drugs for Treating Obesity.

Authors:  Donna H Ryan
Journal:  Handb Exp Pharmacol       Date:  2022

Review 3.  Linking hIAPP misfolding and aggregation with type 2 diabetes mellitus: a structural perspective.

Authors:  Shahab Hassan; Kenneth White; Cassandra Terry
Journal:  Biosci Rep       Date:  2022-05-27       Impact factor: 3.976
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.